Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | CNR2 | P34972 | 2/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | APEX1 | P27695 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3162905 | 0.87 | CYP3A4 (0.53) | USP2TP53CNR2CYP3A4SMN1; SMN2 | |
| SCHEMBL3172022 | 0.86 | CTSL (0.48) | USP2TP53CNR2HSP90AA1CYP3A4 | |
| SCHEMBL3175798 | 0.85 | CNR2 (0.48) | USP2TP53CNR2CYP3A4SMN1; SMN2 | |
| SCHEMBL3178312 | 0.83 | USP2 (0.46) | USP2TP53CNR2HSP90AA1CYP3A4 | |
| SCHEMBL3163060 | 0.82 | USP2 (0.45) | USP2TP53CNR2HSP90AA1CYP3A4 | |
| SCHEMBL3177998 | 0.77 | CYP2C19 (0.52) | TP53CYP3A4SMN1; SMN2CYP2C9CYP2C19 | |
| SCHEMBL19331451 | 0.75 | KDM4E (0.56) | CYP3A4SMN1; SMN2CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL3249278 | 0.74 | APEX1 (0.46) | CYP3A4SMN1; SMN2CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL3172051 | 0.73 | USP2 (0.47) | USP2TP53CYP3A4SMN1; SMN2MAPT | |
| SCHEMBL3170016 | 0.73 | CYP3A4 (0.45) | TP53CYP3A4SMN1; SMN2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7649093-B2 | (2E)-3-[4-[(6-hydroxy-3-methyl-2-phenyl-1-naphthalenyl)oxy]-2-(trifluoromethyl)phenyl]-2-propenoic acid; menopausal or postmenopausal disorders, vasomotor symptoms, vaginal atrophy, atrophic vaginitis, endometriosis, female sexual dysfunction, breast cancer, depression, diabetes, osteoporosis | Glaxo Smith Kline LLC (US) | 2010-01-19 | — | — | US | disclosed |
| US-20070276000-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2007-11-29 | — | — | US | disclosed |
| EP-1773750-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006002185-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276000-A1 | CHEMICAL COMPOUNDS | GPER1, ESR2, ESR1 | USP2 2754/4885TP53 1759/4885CNR2 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.